<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>TRANSLATION</th>
<th>DEVELOPMENT</th>
<th>IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen</td>
<td>Pre-clinical</td>
<td>Phase I</td>
<td>Treatment access</td>
</tr>
<tr>
<td>Hit-to-lead</td>
<td>Phase Ila/Proof-of-concept</td>
<td>Phase IIb/III</td>
<td></td>
</tr>
<tr>
<td>Lead optimization</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SLEEPING SICKNESS**
- SCYX-1330682
- SCYX-1608210

**LEISHMANIASIS**
- Leishmaniasis Hit-to-lead
  - DNDI-5421
  - DNDI-5610
- NTD Drug Discovery Booster Hit-to-lead
  - Amino pyrazoles
- Daiichi Sankyo Hit-to-lead
  - CF series
  - Leishmaniasis L205 series

**CHAGAS DISEASE**
- Hit-to-lead
  - C205 series
- NTD Drug Discovery Booster Hit-to-lead
- Daiichi Sankyo Hit-to-lead

**FILARIA: RIVER BLINDNESS**
- Macrofilaricid 
  - CC6166
- Oxfendazole
- Emodepside
- TyLAMac (ABBV-4083)
- Fosravuconazole

**MYCETOMA**
- 5 FC (cryptococcal meningitis)

**HIV**
- 4-in-1 (ABC/3TC/LPV/r)
- 2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC
- Ravidasvir + sofosbuvir
- Ravidasvir

**HEPATITIS C**
- Fixed-dose combination ASMQ*
- Fixed-dose combination ASAQ*

**MALARIA**
- NCE (New chemical entity)

* Implementation transferred to the Medicines for Malaria Venture in 2015

* Treatments delivered by DNDi

---

**New VL treatments (South Asia)**

**Fexinidazole** for *T. b. gambiense*

**Nifurtimox-eflornithine combination therapy** (NECT)*

**SSG&PM (East Africa)**

**New CL combination**

**New treatments for PKDL**

**Miltetofine + paromomycin combination (Africa)**

**New treatments for HIV/VL**

**Benznidazole paediatric dosage form**

**Super-booster therapy** for children with HIV/TB*

**2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC**